On September 10th in New York City, CASI Pharmaceuticals hosted a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy and recent regulatory reforms impacting the China biopharmaceutical market. The meeting featured presentations by Nobel Prize winning immunologist James P. Allison, Ph.D. and the former head of Chinese National Medical Product Administration(NMPA), the Chinese FDA, Dr. Ruyi He, M.D. In addition to the presentations there was a panel and interactive Q&A session moderated by Brad Loncar, a renowned blogger and pundit on the China pharmaceutical space. Participating in the panel were KOL speakers Dr. James Allison and Dr. Ruyi He along with CASI CEO Wei-Wu He, Ph.D.; Lynda Chin, M.D. and President and CEO of Apricity Health LLC;Lulu Lv, M.D., Ph.D. and CEO of Juventas Cell Therapy; and Jinzi Wu, Ph.D. and Chairman and CEO of Ascletis. Among many subjects addressed on the panel, the group discussed where they saw the biotech industry going in five years and more specifically, where would China’s biopharma industry be in five years.
Event Video